¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½Å ½ÃÀå º¸°í¼­ : Á¦Ç°, ¿ëµµ, Áö¿ªº°(2024-2032³â)
Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2024-2032
»óǰÄÚµå : 1541546
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 136 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½Å ½ÃÀå ±Ô¸ð´Â 2023³â 13¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024³âºÎÅÍ 2032³â±îÁö 5.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

¸®Æ÷¼Øµ¶¼Ò·çºñ½ÅÀº ´Ù¾çÇÑ ÀÚ°¡¸é¿ªÁúȯ°ú °£, À¯¹æ, Àڱ󻸷, À§, ½ÅÀå¾Ï Ä¡·á¿¡ »ç¿ëµÇ´Â È­Çпä¹ý ¾à¹°ÀÔ´Ï´Ù. ü³» ¾Ï¼¼Æ÷ÀÇ Áõ½ÄÀ» ¸·°Å³ª ´ÊÃß´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ ¾àÀº Æä±×È­ ¸®Æ÷¼ØÀÇ Áö¹æÀ¸·Î ½Î¿© Á¤¸Æ Áֻ縦 ÅëÇØ Åõ¿©µË´Ï´Ù. µ¶¼Ò·çºñ½ÅÀ̶ó´Â ¾à¹°Àº ¾Ï¼¼Æ÷°¡ ºÐ¿­Çϰí Áõ½ÄÇÏ´Â µ¥ ÇÊ¿äÇÑ È¿¼Ò¸¦ Â÷´ÜÇϰí, ¸®Æ÷Á»Àº ¾à¹°ÀÌ Ç÷·ù¿¡ ´õ ¿À·¡ ¸Ó¹°·¯ ¾Ï¼¼Æ÷¿¡ µµ´ÞÇÏ¿© È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¾à¹°ÀÇ º¹¿ë·®Àº ȯÀÚÀÇ Ã¼Áß, ½ÅÀå, ÀϹÝÀûÀÎ °Ç°­ »óÅ¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ±âÁ¸ ¾à¹°¿¡ ºñÇØ ¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½ÅÀº µ¶¼º, °ñ¼ö ¾ïÁ¦, Å»¸ðÁõ, ¸Þ½º²¨¿òÀÌ Àû½À´Ï´Ù.

¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½Å ½ÃÀå µ¿Çâ

°ñÀ°Á¾, ´Ù¹ß¼º °ñ¼öÁ¾, ³­¼Ò¾Ï, ÀÚ°¡¸é¿ª°áÇÌÁõÈıº(AIDS) °ü·Ã Ä«Æ÷½ÃÀ°Á¾°ú °°Àº ¸¸¼º ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ´Â ³ëµ¿ Àα¸ÀÇ ´ë´Ù¼ö°¡ ÁÂ½Ä »ýȰ ¹æ½Ä°ú ¹Ù»Û ÀÏÁ¤À¸·Î ÀÎÇØ ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ß»ýÀÌ Å©°Ô Áõ°¡ÇÏ¿© ¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½Å ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Ï Ä¡·á¹ý¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÆÐ·¯´ÙÀÓ ³ª³ë ¾à¹° ¹× °³·®Çü È­Çпä¹ýÁ¦ÀÇ °³¹ß µî ´Ù¾çÇÑ ¹ßÀüÀÌ ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ü³» ¾à¹°ÀÇ ºÎÀ§º° Àü´Þ ¹× ¹æÃâ Á¦¾î¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ±× ¿ÜÀÇ ¿äÀÎÀ¸·Î´Â ÀÇ·á ÀÎÇÁ¶ó, ƯÈ÷ ½ÅÈï±¹°¡ÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ Å©°Ô °³¼±µÇ°í Á¾¾çÇÐ ºÎ¹®ÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸ °³¹ß(R&D) Ȱµ¿ÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¸®Æ÷Á¶¸» µ¶¼Ò·çºñ½Å ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦8Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦9Àå SWOT ºÐ¼®

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global liposomal doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

Liposomal Doxorubicin Market Trends:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.

Breakup by Product:

Doxil/Caelyx

Lipodox

Myocet

Others

Breakup by Application:

Leukemia

Bone Sarcoma

Breast Cancer

Endometrial Cancer

Kidney Cancer

Multiple Myeloma

Kaposi Sarcoma

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Liposomal Doxorubicin Market

6 Market Breakup by Product

7 Market Breakup by Application

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â